Deals channel feed

Am­gen hands off rights to lep­rosy, tu­ber­cu­lo­sis med picked up as part of $13.4B Ote­zla deal

5 years ago
Manufacturing

Rid­ing on rosy es­ti­mates of Zol­gens­ma sales, Re­genxBio sells part of its roy­al­ty for $200M

5 years ago
Cell/Gene Tx

Nek­tar sells off roy­al­ties on its 2 ap­proved drugs for $150M in cash, re­dou­bling fo­cus on I-O can­di­dates

5 years ago

Warp Speed bets $356M to mass man­u­fac­ture a Mer­ck drug for se­vere Covid-19

5 years ago
Coronavirus

A neigh­bor­ly vis­it turns in­to a bid­ding war: How Dan Skovron­sky se­cured Eli Lil­ly's lat­est $1B buy

5 years ago

A busy, buzzy Ver­tex finds a high-pro­file part­ner in the RNA-drug­ging world to launch a fresh dis­cov­ery ef­fort

5 years ago

Look­ing to build a 'd­ual sourcing' sup­ply chain, WuXi Bi­o­log­ics shells out $183M for Bay­er drug sub­stance plant

5 years ago
Outsourcing

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

5 years ago
Cell/Gene Tx

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

5 years ago

Col­orec­tal drug can­di­dates fo­cal point of new col­lab­o­ra­tion be­tween Servi­er, Cel­sius Ther­a­peu­tics

5 years ago

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

5 years ago

Ul­tragenyx bets up to $304M on an old No­var­tis drug for an ul­tra-rare bone dis­ease

5 years ago

Mer­ck­'s Roger Perl­mut­ter con­tin­ues spin­ning deals, putting up $1B+ for Janux Ther­a­peu­tics and its T cell en­gagers

5 years ago

Af­ter los­ing race for first to mar­ket in lu­pus nephri­tis, Au­rinia taps Ot­su­ka for vo­closporin li­cens­ing pact abroad

5 years ago

Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy pipeline

5 years ago

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

5 years ago

Gilead’s Dan O’Day pulls the plug on the li­on’s share of their fil­go­tinib col­lab­o­ra­tion as the FDA erects a high safe­ty bar­ri­er. What went wrong?

5 years ago
FDA+

Take­da’s gene edit­ing part­ner is snapped up for $250M cash as sec­tor con­tin­ues to heat up

5 years ago

Joe Jimenez forges an­oth­er big-mar­ket, small-cash deal, lin­ing up a kid­ney dis­ease drug for his lat­est port­fo­lio start­up

5 years ago

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this year

5 years ago
Cell/Gene Tx

Go­ing to Chi­na? ADC Ther­a­peu­tics spot­lights a new way to do it with Hill­house-backed Over­land

5 years ago
China

No­vo Hold­ings in­vests in Hemab, a com­pa­ny go­ing against the he­mo­phil­ia gene ther­a­py grain with a plan for bis­pecifics

5 years ago
Cell/Gene Tx

Chas­ing Am­gen on KRAS com­bo, Roche dish­es out $75M for Re­lay's SHP2 drug to pair with in-house pro­gram

5 years ago

In an end-of-year sur­prise, As­traZeneca nabs rare dis­ease stal­wart Alex­ion in $39B buy­out. But why?

5 years ago
First page Previous page 81828384858687 Next page Last page
A service from the Financial Times